Abhilash earned his PhD in nanomedicine, focusing on innovative cancer treatments. His thesis was titled "Nanoparticles in Cancer Therapy." Additionally, he successfully defended a trial lecture on the "Pros and Cons of CAR-T Cell Therapy." Abhilash completed his master's in molecular biology in both Sweden and the USA. He brings extensive experience in histology and immunology research, having previously studied regulatory proteins in first trimester trophoblasts and other human pathophysiological tissues. Notably, he identified a novel subset of inflammatory Natural Killer cells (NK17/NK1) in patients with Multiple Sclerosis, a neurodegenerative disease.

Since joining our group in June 2016, Abhilash has been working on novel cancer therapies, specifically targeted therapy using drug-loaded nanoparticles (NPs). His research focuses on studying the toxicity, biodistribution, and treatment response of these nanoparticles in various in vivo mice tumor models. His work aims to enhance the precision and effectiveness of cancer treatments, making them more targeted and less harmful to healthy tissues. Additionally, he is investigating the immune response induced by NPs and examining the presence of immune cells within tumors.